Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.

about

Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling

P2860

Q38634034-F6C07555-B541-442C-99EC-84CD01E25997 Q58796673-C604E506-8B61-4C44-9B94-A0B6F5B04BE3

P2860

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.

Item

http://www.wikidata.org/entity/Q41367801

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Enhancing NK cell-mediated cyt ...... MEK/Erk signaling inhibition.

@en

type

Item

label

Enhancing NK cell-mediated cyt ...... MEK/Erk signaling inhibition.

@en

prefLabel

Enhancing NK cell-mediated cyt ...... MEK/Erk signaling inhibition.

@en

P1476

Enhancing NK cell-mediated cyt ...... MEK/Erk signaling inhibition.

@en

P2093

Li Jun Xu

http://www.w3.org/2001/XMLSchema#string

Li Yang

http://www.w3.org/2001/XMLSchema#string

MingJing Shen

http://www.w3.org/2001/XMLSchema#string

Peter C Keng

http://www.w3.org/2001/XMLSchema#string

Soo Ok Lee

http://www.w3.org/2001/XMLSchema#string

Xiaodong Yang

http://www.w3.org/2001/XMLSchema#string

Ying Tsai

http://www.w3.org/2001/XMLSchema#string

Yuhchyau Chen

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

The PD-1 pathway in tolerance and autoimmunity

The selectivity of protein kinase inhibitors: a further update

Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells

Role of the PD-1 pathway in the immune response

NKG2D ligands as therapeutic targets

Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells

P2888

s41598-017-08483-z

P304

7958

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-08483-Z

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091090403

http://www.w3.org/2001/XMLSchema#string

P698

28801607

http://www.w3.org/2001/XMLSchema#string

P932

5554231

http://www.w3.org/2001/XMLSchema#string

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.

about

P2860

P2860

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932